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Surgical Infection Society Guidelines for Vaccination
after Traumatic Injury
THOMAS R. HOWDIESHELL,1 DAITHI HEFFERNAN,1 and JOSEPH T. DIPIRO2
For the Therapeutic Agents Committee of the Surgical Infection Society

ABSTRACT
Background: Recommendations for vaccination of injured patients against infection are evolving. Newly-recognized infections, safety considerations, changing epidemiology, and redefinition of patient groups at risk are factors that may influence vaccine development priorities
and recommendations for immunization. However, recommendations must often be formulated based on incomplete data, forcing reliance on expert opinion to address some crucial
questions. These guidelines provide evidence-based recommendations for the prevention or
treatment of infectious morbidity and mortality after traumatic injury, such as soft tissue
wounds, human or animal bites, or after splenectomy.
Methods: A panel of experts conducted a thorough review of published literature, as well
as information posted on the internet at the websites of the U.S. Centers for Disease Control
and Prevention, among others. MEDLINE was searched for the period 1966–2004 using relevant terms including “anthrax,” “rabies,” “tetanus,” “tetanus toxoid,” and “ splenectomy,” in
combination with “vaccine” and “immunization.” The Cochrane database was searched
also. Reference lists were cross-referenced for additional relevant citations. All published reports were analyzed for quality and graded, with the strength of the recommendation proportionate to the quality of the supporting evidence.
Results: Recommendations are provided for pre- and post-exposure prophylaxis of rabies
and anthrax. For tetanus prophylaxis, recommendations are provided for prophylaxis of acute
wounds stratified y age and prior immunization status, and for immunization of persons at
high risk. After splenectomy, it is recommended that all persons ages 2–64 years receive 23valent pneumococcal vaccine and meningococcal vaccine, with Haemophilus influenzae type
B vaccine administered to high-risk patients as well (all are Grade D recommendations). Vaccination should be given two weeks before elective splenectomy (Grade C), or two weeks after emergency splenectomy (Grade D). A booster dose of pneumococcal vaccine is recommended after five years (Grade D); no re- vaccination recommendation is made for
meningococcal or Haemophilus influenzae type B vaccine. Recommendations for prophylaxis of splenectomized children under the age of five years are also provided.
Conclusion: There are limited data on the use of vaccines after injury. This document brings
together a disparate literature of variable quality into a discussion of the infectious risks after injury relevant to vaccine administration, a summary of safety and adverse effects of vaccines, and evidence-based recommendations for vaccination.
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of Surgery, University of New Mexico Health Sciences Center, Albuquerque, New Mexico.
Carolina College of Pharmacy, Charleston, South Carolina.
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I

21ST CENTURY, nearly any antigen can be
prepared for use as a vaccine. The difficulties
are in identifying protective antigens and persuading the immune system to respond correctly
to them. Over the last 200 years, success has been
achieved in controlling major infectious diseases
predominantly by vaccinating with attenuated
living or inactivated organisms, inactivated toxoids, or bacterial capsular polysaccharides. Vaccine preparation with attenuated or killed organisms has not required extensive knowledge
of immune responses, except to be sure that antibodies are produced. Control of bacteremia or
viremia has sufficed to provide efficacy against
many of the diseases controlled by vaccination
[1]. Now, more complex problems must be dealt
with, such as microbes that are not inhibited by
antibodies and immune responses that are useless or even pathologic.
In recent years, a better understanding of
protective immune responses has included
recognition of the need to induce both specific
cellular immune responses and antibodies to
control infections. Antibodies on mucosal surfaces and in serum can prevent infection or
limit spread to target organs, whereas T-cell
Th1 and Th2 responses that shift the immune
system toward cellular or antibody-mediated
immunity, respectively, destroy infected cells
and eliminate infection [1].
Recommendations for immunizations are
evolving. Newly recognized infections, safety
considerations, changing epidemiology, and
the identification of new risk groups are important factors that may influence vaccine development priorities and immunization recommendations. In addition, dramatic advances
in molecular biology have made possible the
development of many new and future vaccines
and combination products.
Development of vaccine policy is difficult
and complex work, tempered by judgment and
elements of uncertainty [1]. The recommendations made by the Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC),
the Committee on Infectious Disease of the
American Academy of Pediatrics, and other authorities are not without controversy. Recommendations often must be formulated on the
basis of incomplete data, necessitating vigorous debate to achieve consensus.
N THE
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The purpose of this document is to provide
evidence-based recommendations on the use of
vaccines for the prevention or treatment of infectious morbidity and mortality after traumatic injury. Injuries necessitating immunization include trauma necessitating splenectomy,
human or animal bites, and other soft tissue
wounds. In addition, the threat of biologic
agent attacks has added the potential for infection with microorganisms such as anthrax.
There are limited data on the current use of
vaccines after injury. Although recommendations for the use of rabies and tetanus vaccines
exist, their utility after injury is poorly documented [2,3]. A 2002 survey of 557 trauma surgeons documented a lack of consensus regarding the immunization of post-splenectomy
patients [4].
This document presents a focused review of
the infectious risk after injury, evidence supporting the use of vaccines in these circumstances, a summary of safety and adverse effects
of vaccines, and evidence-based recommendations for vaccination after injuries that carry a
risk of rabies or tetanus and after splenectomy.
In addition, a recommendation is provided for
use of anthrax vaccine.

METHODS
The recommendations were developed by an
expert panel, who conducted a thorough review of the published literature as well as the
information available on federal government
internet sites such as that of the CDC
(www.cdc.gov). The MEDLINE database was
searched using multiple strategies to identify
clinical trials of efficacy and reports of adverse
events published from 1966 to 2004, and this
was supplemented by manual search of references from all relevant journal articles. The
terms used for these searches included “anthrax,” “rabies,” “tetanus,” “tetanus toxoid,”
and “splenectomy,” in combination with the
terms “vaccine” and “immunization.” In addition, the Cochrane database was searched for
any relevant documents.
All published reports were categorized by
quality, and each trial was graded according to
the method described in Table 1 [5]. Large randomized trials with clear-cut results were given

SURGICAL INFECTION SOCIETY GUIDELINES FOR VACCINATION

the greatest weight, followed by small randomized trials and then by non-randomized
studies. The lowest quality of evidence included case studies, uncontrolled studies, and
expert opinion. A recommendation grade of A,
B, or C had to be supported by randomized trials. An executive summary of the graded recommendations is presented in Table 2.
The document has been reviewed and endorsed by the Therapeutic Agents Committee
and the Executive Council of the Surgical Infection Society.

RESULTS
Rabies
Risk of rabies after injury. Rabies is a viral infection transmitted in the saliva of infected animals. The infection is widespread in some animal species, and occasionally is transmitted to
human beings. Over the last 50 years, the incidence of rabies has declined significantly in the
industrialized world, although developing nations still have a high case rate. The geographic
distribution of human cases generally follows
the distribution of animal cases, but persons returning from endemic areas may import the
disease to non-endemic areas [6].
Although human rabies infection is rare in
the U.S., animal bites are encountered frequently in clinical practice, as several million
TABLE 1.

RECOMMENDATIONS AND EVIDENCE
GRADING SYSTEM

Grading of recommendations
A. Supported by at least two level I investigations
B. Supported by one level I investigation
C. Supported by level II investigations only
D. Supported by at least one level III investigation
E. Supported by level IV or V evidence
Grading of evidence
I. Large randomized trials with clear-cut results;
low risk of false-positive (alpha) error or falsenegative (beta) error
II. Small randomized trials with uncertain results;
moderate to high risk of false-positive (alpha)
and/or false-negative (beta) error
III. Nonrandomized, contemporaneous controls
IV. Nonrandomized, historical controls and expert
opinion
V. Case series, uncontrolled studies, and expert
opinion
Adapted from Sackett [5].
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U.S. residents are victims each year. Dog bites
alone account for more than 300,000 emergency
department visits annually, with total costs of
more than $100 million [7].
Rabies is invariably fatal in the absence of
specialized treatment, but is preventable with
proper measures, including prophylaxis after
certain types of animal exposure. Control of rabies in domestic animal populations and postexposure prophylaxis has led to a decline in annual human rabies cases in the U.S. from more
than 100 at the beginning of the 20th Century
to 1 to 3 per year. Only 32 cases of human
rabies were diagnosed in the U.S. between 1980
and 1998 [6].
Since the 1970s, the expanding epizootic of
rabies in raccoons in the eastern U.S. has increased concern about potential transmission
to man. In 1997, 8,509 animal rabies cases were
reported in the U.S., an increase of 19.4% from
1996 [8]. Rabies appears to be expanding in raccoons, and reports of rabies in cats have increased in the same areas. Although no documented human infections have occurred with
the raccoon rabies virus variant, the use of rabies post-exposure prophylaxis has increased
recently [9]. In 1987, approximately 18,000 rabies post-exposure prophylaxis treatments
were given in the U.S., whereas in 1997, an estimated 39,000 treatments were given. Although the costs of rabies post-exposure prophylaxis can vary greatly, the cost in the U.S.
is approximately $1,500 per course for biologics alone. Physician and follow-up clinic
charges add to the cost [10].
Pathogenesis. Rabies is an acute progressive
encephalitis caused by RNA viruses in the family Rhabdoviridae, genus Lyssavirus [11]. Rabies
virus is the only known lyssavirus in the New
World. Some locations are considered rabiesfree; among them are Hawaii and many Pacific
and Caribbean islands (except Cuba, Dominican
Republic, Haiti, Grenada, and Puerto Rico).
However, their continued freedom from rabies
depends on prevention of the introduction of
the virus and laboratory-based surveillance [12].
The rabies virus is highly neurotrophic and
is restricted to nervous tissue during most of
the course of infection. There is no viremia.
After inoculation, the virus may enter the peripheral nerves immediately, but usually there
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TABLE 2.

EXECUTIVE SUMMARY

OF

GRADED RECOMMENDATIONS

FOR

VACCINATION

OF INJURED

PATIENTS

Rabies
Pre-exposure prophylaxis
Vaccination should be provided to persons at risk (laboratory workers, diagnosticians, veterinarians and their
staffs, animal control officers, rabies researchers, and some travelers to areas where rabies is prevalent) (Grade A)
Post-exposure prophylaxis
A five-dose regimen is recommended. Five one-milliliter doses of vaccine are given intramuscularly (deltoid
muscle) on days 0, 3, 7, 14, and 28 in conjunction with a single dose of human rabies immune globulin (HRIG) 20
IU/kg infiltrated into the wound on day 0. Any remaining HRIG should be administered IM at a site distant
from the vaccine site (Grade D)
Anthrax
Pre-exposure prophylaxis
Vaccination may be indicated for veterinarians and other high-risk persons handling potentially infected
animals in areas with a high incidence of anthrax. Routine vaccination of emergency first-responders, federal
responders, medical practitioners, and private citizens is not recommended (Grade B)
Post-exposure prophylaxis
Administration of the vaccine and antibiotics against B. anthracis is recommended following an aerosol
exposure to spores. Post-exposure vaccination should be administered as three injections of vaccine, beginning as
soon as possible, at 0, 2, and 4 weeks (Grade E)
Tetanus
Prophylaxis of acute wound
Administration of tetanus immune globulin (HTIG) 250 IU is recommended only for patients with tetanusprone wounds who have never completed a primary immunization series. The HTIG should be given at a site
different from the tetanus toxoid to avoid interaction (Grade B)
For small children, the routine dose of HTIG may be calculated by body weight (4 IU/kg). However, it may be
advisable to administer the entire 250 IU, because theoretically, the same amount of toxin will be produced in a
child’s as in an adult’s body (Grade B)
If a patient with an acute soft tissue injury has not been immunized previously, a tetanus toxoid booster is
required. The patient must have followup to complete the series. If the patient has been immunized previously, a
booster dose is given if the last dose was more than five years previously (for a tetanus-prone wound) or more
than 10 years previously (for a non-tetanus-prone wound). Patients with a contraindication to tetanus toxoid must
be managed with HTIG alone (Grade B)
Immunization of high-risk persons
The elderly, HIV-infected, or otherwise immunocompromised patient may not respond adequately to
vaccination alone. More liberal use of HTIG may be warranted for these patients, regardless of primary
immunization status. More frequent dosing of tetanus toxoid may help to sustain adequate antibody titers
(Grade E)
Intravenous drug users may present with complaints unrelated to acute wounds. However, their drug use
should be considered a risk factor that requires consideration of tetanus prophylaxis (Grade E)
Vaccination after Splenectomy
The 23-valent polysaccharide pneumococcal vaccine is recommended for persons 2 to 64 years of age who have
functional or anatomic asplenia (Grade D)
High-risk individuals should be considered for vaccination with Haemophilus influenzae type B conjugate vaccine
(Grade D)
Asplenic patients should receive meningococcal vaccine (Grade D)
Timing and redosing
For patients undergoing elective splenectomy, vaccination should be performed at least two weeks before
surgery to maximize the antibody against T-cell-dependent immunogens (Grade C)
Patients who undergo emergency splenectomy should receive immunizations 14 days postoperatively
(Grade D)
A single revaccination with the 23-valent polysaccharide pneumococcal vaccine should be given at least five
years after the first dose. No further dosing is recommended routinely (Grade D).
There is currently no recommendation to revaccinate for H. influenzae type B or meningococcus
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EXECUTIVE SUMMARY

OF

GRADED RECOMMENDATIONS

FOR

VACCINATION

OF INJURED
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PATIENTS (CONTINUED)

Vaccination of children younger than five years
The 7-valent pneumococcal conjugate vaccine is recommended for all children 24 to 59 months of age who are
at high risk for invasive pneumococcal infection. High-risk children include those with sickle cell disease and
other types of functional or anatomic asplenia. For high-risk children 24 to 59 months of age who have received
no previous dose of either the 23-valent or the 7-valent pneumococcal polysaccharide vaccine, two doses of the
7-valent conjugate vaccine are recommended, to be given at an interval of six to eight weeks, followed by a single
injection of the 23-valent vaccine no less than six to eight weeks after the last dose of the 7-valent vaccine. An
additional dose of 23-valent vaccine is recommended three to five years after the last dose (Grade D)
High-risk children 24 to 59 months of age should also receive vaccination against meninococcus and H.
influenzae type B (Grade D)
Antibiotic prophylaxis is recommended for all children with sickle cell disease and functional or anatomic
asplenia, regardless of whether they have received pneumococcal immunization (Grade B)
Oral penicillin V potassium is recommended in a dose of 125 mg twice a day, until three years of age and in a
dose of 250 mg twice a day after three years of age. Children who have not experienced invasive pneumococcal
infection and have received recommended pneumococcal immunizations may discontinue penicillin prophylaxis
after five years of age (Grade B)

is an incubation period during which the virus
is amplified. The virus then crosses the myoneural junction and enters the nervous system
through unmyelinated sensory and motor axons. Rabies can be prevented only by post-exposure immunization during this incubation
period, before the virus enters the central nervous system. The virus moves rapidly through
axons until it reaches the spinal ganglia. At this
time, the first symptoms of the disease (pain
and paresthesia at the wound site) may appear.
The virus then disseminates quickly in the central nervous system, causing rapidly progressive encephalitis that is fatal in the absence of
sometimes-heroic treatment measures [13].
Transmission. In nature, the rabies virus is labile, being inactivated by sunlight, heat, desiccation, and other environmental factors. Thus,
it is not viable outside the host. Exposure occurs when there is penetration of the skin by
teeth or direct transdermal or mucosal contact
with infectious material, such as brain tissue or
saliva. Almost all cases are caused by bites from
infected mammals.
All mammals are susceptible and can transmit rabies virus, but true reservoirs, which are
responsible for long-term disease maintenance,
persist only among Carnivora and Chiroptera
(bats) [12]. Specific viruses are adapted to these
hosts and typically perpetuate infection within
a species by transmission before the host dies.
In North America, raccoons, skunks, bats,
foxes, coyotes, and bobcats are the primary
reservoirs. Unvaccinated domestic animals and

human beings become rabid after exposure to
such reservoirs. By definition, all reservoirs are
capable of transmitting infection, but not all potential vectors are reservoirs. For example, livestock die of the disease before transmitting it.
Cats, usually infected by dogs or wild animals,
are effective vectors but do not sustain the disease [14].
In developed countries, the incidence of human exposure to rabid domestic animals has
decreased as a result of improved canine vaccination. Whereas more than 9,000 rabid dogs
were reported in the U.S. in 1944, fewer than
100 were identified in 2002 [12]. Because cats
are popular but less well supervised and less
often vaccinated than dogs, rabid cats now outnumber rabid dogs. Rabies in small mammals
such as mice and squirrels is rare, and transmission from them to humans remains undocumented. Larger rodents, such as woodchucks,
are more frequently reported to be rabid [14].
“Cryptic” human rabies cases, in which there
is no history of exposure to a rabid animal, are
now the norm in the U.S. Molecular characterization has determined that the majority of
these cases are associated with bat rabies
viruses [15]. Bat bites are not dramatic and may
not be appreciated when they occur or when
the patient is examined. In other cases, people
may recognize that a bite has occurred, but may
not comprehend its implications or may believe
that the risk of rabies is exceedingly low. Certain persons, such as young children or persons
with disabilities, may be unable to provide an
accurate history of a bite [16].
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Since 1960, exposures other than bites have
resulted in fewer than 35 documented human
rabies cases. Most of the reported cases were
attributable to poorly inactivated vaccine or to
organ transplantation. Although extremely uncommon, transplantation of tissue from a
donor with rabies will have disastrous consequences for the transplant recipient, as has been
described recently [17]. No cases in human beings after indirect, non-bite exposure, such as
touching a pet that may have been exposed to
a rabid animal, have been reported. Theoretically, human-to-human transmission is possible, but no cases have been documented among
healthcare workers [18].
Clinical presentation and diagnosis. The clinical
course of rabies in humans is acute, usually
progressing from initial symptoms to death
within two to three weeks, even with intensive
supportive care. The incubation period can
range from a few days to several years, depending on the infecting strain. The period also
is believed to be inversely related to the size of
the inoculum and the proximity of the bite to
the central nervous system. The subsequent
clinical course can be described in three stages.
In the prodromal stage, the symptoms and
signs include fever, anorexia, nausea, vomiting,
and malaise. Approximately one-half of the patients develop pain or paresthesia at the wound
site. Within a few days, neurologic symptoms
such as anxiety, agitation, irritability, or insomnia may become manifest. The acute neurologic stage follows, with objective signs of
central nervous system involvement. Most patients have “furious” rabies, characterized by
marked hyperactivity, disorientation, hallucination, or bizarre behavior. This hyperactivity
later becomes intermittent and may be spontaneous or precipitated by tactile, auditory, or visual stimuli. Hydrophobia—spasm of the pharynx and larynx provoked by drinking or the
sight of water—and aerophobia—a similar effect produced by air currents on the patient’s
face—are considered hallmarks of the disease.
Seizures may also appear during this stage, as
can dysfunction of the autonomic nervous system. A few patients die during this stage, but
most go on to develop progressive paralysis
and eventually coma. In some patients, the par-
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alytic state dominates the entire clinical picture.
Paralysis or paresis involves the proximal muscles and can be accompanied by constipation,
urinary retention, or respiratory failure. In patients receiving intensive supportive care, the
average duration of illness between the onset
of paralysis and death is approximately seven
days. Once neurologic symptoms have developed, survival is rare. With one exception [19],
the only survivors recorded so far had received
post-exposure prophylaxis or had been vaccinated previously [18].
Human rabies in the U.S. is rare, but also underdiagnosed. The diagnosis can be elusive if
a history of animal exposure is not obtained.
Hydrophobia and aerophobia, pathognomic
when present, may be absent. Rabies, along
with tetanus, Guillain-Barré syndrome, transverse myelitis, and toxic ingestion, should be
considered in the differential diagnosis of any
rapidly progressive encephalitis even if the history of bite is not available. It also is important
to exclude other treatable encephalitides such
as herpes encephalitis [20].
Routine laboratory tests and diagnostic
studies are of little value in the diagnosis of
rabies. Examination of the cerebrospinal fluid
may show leukocytosis, but protein and glucose concentrations are often normal. Computed tomography and magnetic resonance
imaging scans may be normal even in the presence of advanced rabies encephalitis. Therefore, specific diagnostic tests are necessary
that include virus antigen detection, serologic
studies, virus culture, and histopathologic
examination. Virus antigen can be detected
when a 6-mm punch biopsy of the skin from
the nape of neck is stained with immunofluorescent rabies antibody, which reveals the
antigen in sensory nerve endings at the base
of hair follicles. This test is positive in 50% of
patients in the first week of illness. Immunofluorescent antibody staining of the epithelial
cells of the cornea (corneal impression test) can
also help with the diagnosis. Seroconversion,
in unvaccinated individuals, usually happens
in the second week of illness, although it can
be delayed by several days. In individuals
who have been vaccinated, it is difficult to distinguish between infection and vaccination
serologically, but measurable spinal fluid
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titers and very high serum antibody titers suggest infection. Rabies virus also can be cultured from saliva, throat, tracheal secretions,
cerebrospinal fluid, or brain biopsy specimens,
but the yield is low. Postmortem examination
of the brain reveals perivascular inflammation
of the gray matter, neuronal degeneration, and
the characteristic cytoplasmic inclusions called
Negri bodies [13].
Description of rabies vaccine and human rabies
immunoglobin. The Imovax Rabies Vaccine®
(Aventis Pasteur, Lyon, France) is a sterile, stable, freeze-dried suspension of rabies virus prepared from strain PM-1503-3M (Wistar Institute, Philadelphia, PA). The virus is harvested
from infected human diploid cells, concentrated by ultrafiltration, and inactivated by
beta-propiolactone. One dose of reconstituted
vaccine contains less than 100 mg of albumin,
less than 150 mcg of neomycin sulfate, and 20
mcg of phenol red indicator. There is no preservative or stabilizer. The vaccine therefore
should be used immediately after reconstitution or discarded. The potency of one dose (1
mL) is 2.5 IU of rabies antigen.
A single dose (20 IU/kg) of human rabies immune globulin (HRIG) should be given at the
beginning of anti-rabies prophylaxis to provide
protection for the first two weeks until the vaccine elicits an antibody response. All patients
should receive HRIG except those who have
previously received a cell culture vaccine as
pre-exposure or post-exposure prophylaxis or
who have documented rabies antibody titers
after receiving another vaccine [20]. Even if
there is a substantial delay between exposure
and initiation of post-exposure prophylaxis,
HRIG should be given. It can be given as late
as the seventh day after vaccine administration,
after which the vaccine should have elicited an
antibody response. If possible, the full dose of
HRIG should be infiltrated into the wound, and
any remaining volume should be administered
IM at a site distant from the vaccine site. The
immune globulin should never be delivered in
the same syringe as the vaccine [20].
Adverse reactions. Once initiated, rabies prophylaxis should not be interrupted or discontinued because of local or mild systemic reac-
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tions to the vaccine. Reactions after vaccination
with human diploid cell vaccine (HDCV) are
less common than with previous vaccines. In a
study using five doses of HDCV, local reactions
such as pain, erythema, and swelling or itching at the injection site were reported by approximately 25% of recipients, and mild systemic reactions such as headache, nausea,
abdominal pain, muscle aches, or dizziness
were reported by 20%. A small percentage of
recipients experienced immune complex reactions characterized by generalized urticaria,
arthralgias, arthritis, angioedema, or malaise
developing typically 2 to 21 days after administration of the booster dose of HDCV. These
reactions have been attributed to the presence
of beta-propiolactone-altered human albumin
in the HDCV [21,22]. Local reactions usually
can be managed with anti-inflammatory
agents. Steroids should not be given because
they can interfere with the development of immunity to the vaccine. When a person has a serious hypersensitivity reaction to the vaccine,
revaccination should be undertaken only after
careful consideration of the risk of acquiring rabies and then should be supervised carefully,
with epinephrine readily available to counteract any anaphylactic reactions [23].
The HRIG can cause pain and low-grade
fever. There have been no specific reported adverse reactions to HRIG, although immune
globulins have been associated with angioneurotic edema, nephrotic syndrome, and anaphylaxis [20].
Evidence-based recommendations. The efficacy
of pre-exposure immunization was documented by high-titer antibody responses to the
Imovax Rabies Vaccine in trials conducted in
England, Germany, France, and Belgium
[24–27]. Seroconversion often was obtained
with only one dose. With two doses one month
apart, 100% of the recipients developed specific
antibody, with a geometric mean titer of approximately 10 IU/mL. In the U.S., Imovax Rabies Vaccine resulted in geometric mean titers
of 12.9 IU/mL at day 49 and 5.1 IU/mL at day
90 when three doses were given intramuscularly over one month [28].
Post-exposure efficacy of the Imovax Rabies
Vaccine was proved during clinical experience
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in Iran, where 45 persons received the vaccine
after being bitten by rabid dogs or wolves. All
except one also received one injection of HRIG.
In contrast to the experience with other vaccines, this treatment protected all of the individuals against rabies [29].
The ACIP publishes protocols for prevention
of human rabies in the U.S. [20]. The information presented in this article is consistent with
the ACIP guidelines. The recommendations of
the American Academy of Pediatrics are in accord with those of the ACIP. Vaccine doses during post-exposure prophylaxis are equivalent
in adults and children [30].
Pre-exposure prophylaxis. The ACIP recommends three injections of 1 mL each of Imovax
Rabies Vaccine, one on day zero, one on day
seven, and one on either day 21 or day 28. It is
recommended that vaccination be provided to
persons at risk (laboratory workers, diagnosticians, veterinarians and their staffs, animal control officers, rabies researchers, and some travelers to areas where rabies is prevalent) before
exposure [20,28] (Grade A). This strategy simplifies the management of a subsequent exposure because fewer vaccine doses are needed
and HRIG is not required. Routine serologic
analysis for verification of the presence of
virus-neutralizing antibody is unnecessary after primary vaccination unless major interruptions in the schedule occur or questions arise
about immune competence. Thereafter, the
need for routine booster vaccination may be
monitored by serologic testing performed
every six months to two years as long as the
person remains at risk. If titers fall below a minimal acceptable value (complete neutralization
at a serum dilution of 1:5), a single vaccine
booster dose is administered. Persons who
work with rabies virus in research laboratories
or vaccine production facilities are at highest
risk of exposure and should have their rabies
antibody titers checked every six months.
Other laboratory workers (those performing rabies diagnostic testing), spelunkers, veterinarians and their staffs, and animal control and
wildlife officers in areas where animal rabies is
enzootic, also should have antibody measurements done every two years [31].
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Post-exposure prophylaxis. Bites from bats and
high-risk wild carnivores such as raccoons,
skunks, foxes, bobcats, and coyotes warrant
consideration of immediate post-exposure prophylaxis. In the case of direct contact between
a person and a bat, the possibility of a bite
should be considered unless the exposed person can be reasonably certain that a bite did not
occur. Post-exposure prophylaxis should be
considered for persons who were in the same
room as a bat, and who might be unaware or
unable to communicate that a bite occurred
[30]. Rabies has been reported in large rodents
(woodchucks and beavers) in areas where rabies is enzootic. Rabies has been diagnosed
rarely in small mammals such as rabbits and
small rodents (squirrels, chipmunks, rats, hamsters, gerbils, guinea pigs, and mice), and there
has never been a documented case of transmission from these small mammals to a human
being. Post-exposure prophylaxis may be considered for the latter in unusual circumstances
(a bite from a small mammal with a history and
clinical signs compatible with rabies), unless
the animal tested negative. An apparently
healthy dog, cat, or ferret that bites a person
should be confined and observed daily for ten
days. The animal should not receive rabies vaccine during the observation period. A veterinarian should evaluate the animal at the first
sign of illness. Management of animals other
than dogs, cats, and ferrets depends on the
species, the circumstances of the bite, the local
rabies epidemiology, and the biting animal’s
history, health status, and potential for exposure to rabies. Because prior vaccination of any
animal may not be 100% effective, current vaccination does not preclude the necessity for an
observation period, or as warranted, euthanasia and testing. If the animal exhibits signs of
rabies during the ten-day observation period,
the exposed person should immediately begin
to receive prophylaxis, and the animal should
be euthanized and its brain tissue tested for rabies. If the animal is confirmed to have rabies,
post-exposure prophylaxis should be completed, whereas if the test results are negative,
post-exposure prophylaxis can cease. Diagnostic testing of brain tissue should be completed
within 24–48 h so that a decision about start-
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ing post-exposure prophylaxis can be made. If
testing will take longer, prophylaxis should be
started, pending the results of testing [30].
Post-exposure prophylaxis consists of three
primary elements: Wound care, infiltration of
HRIG, and vaccine administration. Immediate,
thorough washing of all bite wounds and
scratches with soap and water is perhaps the
most effective measure for preventing rabies.
In experimental animals, local wound cleansing markedly reduces the likelihood of rabies
[32]. Post-exposure anti-rabies immunization
should always include administration of HRIG
and vaccine, with one exception. Persons who
have been immunized previously with the recommended pre-exposure or post-exposure regimens of HDCV, or who have been immunized
with other types of vaccines and have a documented adequate rabies antibody titer, should
receive vaccine only [30].
The ACIP recommends a five-dose regimen
for post-exposure prophylaxis. Five 1-mL
doses of Imovax Rabies Vaccine are given in
the deltoid muscle on days 0, 3, 7, 14, and 28
in conjunction with a single dose of HRIG 20
IU/kg on day 0. As much as possible of the
dose of HRIG should be infiltrated into the
wound. Any remaining volume should be administered IM at a site distant from the vaccine
site [20, 29] (Grade D).
Anthrax
Biological warfare. The clinical disease known
as anthrax is caused by Bacillus anthracis, a
gram-positive, spore-forming bacillus capable
of infecting human and animal hosts. Several
factors affect the destructive capabilities of anthrax as a biological weapon. The delivery of
spores has been a major obstacle to the creation
of widespread anthrax contamination. Spores
can be spread easily in the air by missiles, rockets, aerial bombs, or sprayers, but the accompanying explosions damage the anthrax particles considerably [33]. Particle size also affects
virulence and infective potential. When a particle is larger than 5–10 micrometers, infectivity may decrease substantially, as the 8,000 to
10,000 spores necessary for infection may not
be inhaled. One- to two-micrometer spores are
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highly lethal, but the creation of stable spores
smaller than five micrometers has not been
reported outside state-sponsored laboratories
[33]. Also, the concentration of the powder
affects the quality of the anthrax. The U.S.
has produced the most concentrated anthrax
known, with as many as one trillion spores per
gram. Lastly, clumping of multiple spores limits wide-spread dissemination. To limit this
clumping, sophisticated processing is carried
out with substances such as silica and treatment to offset the electrostatic charge of the
particles to allow maximum dispersal. Anthrax
spores that are smaller than five micrometers
and have been treated to prevent clumping and
then concentrated are referred to as “highgrade” or “weapons-grade” anthrax [34].
Pathogenesis. Anthrax is worldwide in prevalence and affects primarily herbivores that
while grazing ingest spores imbedded in the
soil, which may harbor the bacteria for years.
In humans, the anthrax toxin consists of three
proteins that combine for the lethal effect (see
below). The toxin affects neutrophils and
macrophages, inhibiting bacterial phagocytosis
and preventing the oxidative burst of neutrophils [35].
Clinical presentation. The human disease has
three forms: Cutaneous, pulmonary, and gastrointestinal. The incubation period is generally
2–60 days. In developed countries, 95% of affected patients have the cutaneous form, acquired by contact with infected goats, sheep, or
cattle. The cutaneous form starts as a painless
pruritic papule resembling an insect bite, sometimes surrounded by vesicles. This papule develops into an ulcer with a necrotic center. The
lesions usually start on the extremities and
spread to the head and neck. Lymphadenopathy with systemic signs and symptoms of fever,
malaise, and headache may accompany the cutaneous lesions. The case-fatality rate of cutaneous anthrax is 20% without antibiotic treatment but less than 1% with treatment [36].
Many public health and U.S. State Department officials believe that the most likely scenario for a biological attack using anthrax
would be a release of aerosolized spores over
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densely populated areas, causing large numbers of cases of pulmonary anthrax [33]. The
pulmonary or inhalational form can result from
the inhalation of concentrated spores in a biological attack, but it has also been described in
handlers of Pakistani goat hair in textile workers in Switzerland and the U.S. [37]. The presentation of the pulmonary form is classically
biphasic but can be variable. Early symptoms
can mimic an upper respiratory infection with
a dry cough, low-grade fever, and malaise for
several days. As the symptoms become apparent, the process can involve the hilar and mediastinal lymph nodes, causing substernal
pain, bloody pleural effusions, and a wide mediastinum on chest radiography. A fulminant
acute phase develops later with severe respiratory distress, high fever, meningitis, and
shock. Hemorrhagic mediastinitis is considered a pathognomic sign. The pulmonary form
is invariably fatal if untreated and 80% fatal if
treated after the onset of symptoms [38].
Ingestion of contaminated meat causes gastrointestinal anthrax. Some of the abdominal
manifestations are nonspecific, including abdominal pain, fever, nausea, and vomiting.
More severe symptoms can also occur, including upper or lower gastrointestinal bleeding or
peritonitis. The gastrointestinal type can
progress to death within five days. It has never
been described in the U.S. [39].
On recognizing the symptoms of anthrax,
health care workers should send any affected
body fluids for culture. These specimens would
include material from vesicles, pleural fluid,
cerebrospinal fluid, and stool. Standard blood
cultures should yield large gram-positive
bacilli within 6–24 h, and the clinical laboratory
should be alerted to the possibility of anthrax
so the organism is not dismissed as a skin contaminate. Sputum culture and gram stain are
unlikely to be diagnostic. An enzyme-linked
immunosorbent assay (ELISA) is available only
in a national reference laboratory [33,37].
Vaccine description. The anthrax vaccine is an
inactivated cell-free filtrate of B. anthracis adsorbed to aluminum hydroxide (BioThrax®,
Bioport Corporation, Lansing, MI). Anthrax
manifestations are the result of three major
toxins: Protective antigen (PA), lethal factor
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(LF), and edema factor (EF). Lethal factor is a
zinc metalloprotease that inhibits mitogenactivated protein kinase. Edema factor is a
calmodulin-dependent adenylate cyclase that
generates cyclic adenosine monophosphate in
the cytoplasm of eukaryotic cells. Protective
antigen, the only major antigen in the vaccine
[40,41], is an 82-kD protein that binds to receptors on most mammalian cells. It is then
cleaved by a cell surface protease, exposing a
site that binds competitively to either EF or LF,
creating a complex that enters the cell.
The vaccine is recommended for administration to adults 18 to 65 years of age in six subcutaneous injections at 0, 2, and 4 weeks and at
6, 12, and 18 months. An annual booster injection is recommended to maintain immunity.
Shorter vaccination schedules are being investigated. With this administration schedule, antibody titers to PA peak within 14 days after
the third dose [42], and 95% of vaccinated individuals seroconvert with a four-fold increase
in anti-PA titer. However, the protective titer
has not been defined, and the duration of protection is not known [43].
Vaccine efficacy. Because of the infrequent occurrence of natural infection and the unpredictability of human-induced exposure, the efficacy of the vaccine is unclear. Only one
controlled trial in human beings has been published, and it is more than 40 years old [44].
This was a single-blind, placebo-controlled trial
of approximately 800 mill workers at risk of infection from animal products (379 received vaccine and 414 received the placebo injection).
The vaccine efficacy was 92.5% (the lower 95%
confidence limit was 65%).
Adverse reactions. Many individuals have received the vaccine in military and civilian programs in recent years, providing a reasonable
assessment of the risk of adverse effects. In a
summary of prelicensure vaccine administration to 7,000 individuals, severe local reactions
occurred in 1%, moderate local reactions
(edema and induration) in 2%, and mild local
reactions in 20% of recipients. Systemic reactions (e.g., fever, chills, body aches) were reported by fewer than 0.1% of vaccinees [44].
From 1990 to 2000, 1,544 adverse events were
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reported to the Vaccine Adverse Event Reporting System (VAERS), of which 5% were serious [45]. The most frequent were injection site
hypersensitivity, injection site edema, pain,
headache, arthralgia, and pruritus. There were
two reports of anaphylaxis, and two deaths
were associated with the vaccine, but a causal
relationship was not established. The incidence
of adverse effects per dose of vaccine cannot be
ascertained from the available data.
More than 425,000 military service personnel
received more than 1.6 million vaccine doses
from 1998 to 2000, and “no patterns of unexpected local or systemic adverse events have
been identified” [46]. A review of the experience of 1,583 employees of the Army Medical
Research Institute of Infectious Diseases who
received the vaccine over the past 25 years
demonstrated that 1% of inoculations were associated with systemic effects [47]. The most
frequent adverse effects were headache (0.4%)
and local or injection site reactions (2.6%). In
one series of almost 5,000 vaccinated military
personnel, most adverse events were localized,
minor, and self-limited, including arthralgia,
headache, and fatigue [46].
The potential for congenital anomalies in
children when the vaccine is administered to
their mothers in the first trimester of pregnancy
has not been studied. Therefore, the vaccine is
not licensed or recommended for use in pregnancy and is rated Pregnancy Category D by
the Food and Drug Administration. The ACIP
recommends that pregnant women be vaccinated against anthrax only if the potential benefits outweigh the potential risk to the fetus
[38].
The Institute of Medicine concluded that although no significant adverse effects of the anthrax vaccine have been reported, the evidence
is inadequate to determine whether an association exists between anthrax vaccination and
long-term health outcomes [48]. The CDC concluded that the chronic multi-system illness experienced by some Persian Gulf War veterans
was not associated with the vaccine or other
specific anthrax exposures [49].
Evidence-based recommendations. There is insufficient evidence to document the efficacy of
the anthrax vaccine in individuals who are ex-
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posed or have high risk of exposure to anthrax.
Pre-exposure efficacy has been documented
only in mill workers who were exposed in the
workplace [44]. Despite the lack of clinical trial
data, anthrax vaccine is recommended in certain individuals by the ACIP [38,50].
Pre-exposure prophylaxis. For pre-exposure
prophylaxis, anthrax vaccine use should be
based on quantifiable risk of exposure. The vaccine should be administered by subcutaneous
injection at 0, 2, and 4 weeks and then at 6, 12,
and 18 months [38]. Groups at risk for repeated
exposure should be given priority for vaccination, including: All U.S. active and reserve-duty
military personnel; laboratory personnel handling environmental specimens; workers who
will be making repeated entries into known B.
anthracis spore-contaminated areas after a terrorist attack; and workers in other settings in
which repeated exposure to aerosolized B. anthracis spores might occur. Laboratory workers
using standard Biosafety Level 2 practices in the
routine processing of clinical samples or environmental swabs are not considered at increased risk. Routine vaccination of veterinarians in the U.S. is not recommended because of
the low incidence of animal cases. However, vaccination might be indicated for veterinarians and
other high-risk persons handling potentially infected animals in areas with a high incidence of
anthrax. Routine vaccination of emergency firstresponders, federal responders, medical practitioners, and private citizens is not recommended
[38,44,50,51] (Grade B).
Post-exposure prophylaxis. Post-exposure vaccination should be administered as follows:
Three injections of vaccine, one as soon as possible and the others at two and four weeks.
Post-exposure prophylaxis with the vaccine
and antibiotics against B. anthracis is recommended following an aerosol exposure to
spores [38] (Grade E). The vaccine is effective
at preventing disease in non-human primates
after exposure [52,53].
A major issue with post-exposure prophylaxis is how long antimicrobial therapy should
be given when the vaccine is used. The ACIP
recommends at least a 30-day course of
ciprofloxacin or doxycycline post-exposure for
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persons who have been vaccinated partially or
fully. Antibiotics should be administered at
least until the third vaccine dose is given [38].
Although the shortened vaccine regimen has
been effective post-exposure when co-administered with antibiotics, the duration of protection from vaccination is not known. Because
human-to-human transmission has not been
documented, contacts and friends do not need
prophylaxis unless they also were exposed to
the aerosol [38].
Tetanus
Epidemiology, etiology, and pathophysiology.
Since 1975, fewer than 100 cases of tetanus have
been reported annually in the U.S., and for the
past ten years, the number has averaged less
than 50 per year [54]. Thus, tetanus has become
rare, ranking in frequency behind botulism,
brucellosis, leprosy, Rocky Mountain spotted
fever, and typhoid fever. This situation can be
attributed to several factors, including a decrease in environmental exposure to Clostridium tetani, better management of tetanus-prone
wounds, and universal immunization of children and military personnel. Because the primary tetanus toxoid (TT) series induces excellent immune memory, booster doses reliably
result in a brisk anamnestic antibody response,
even when intervals of 20 years or more have
elapsed since the last dose. Therefore, an antitoxin concentration below 0.1 IU/mL (the generally accepted minimum protective concentration) is strong evidence that either the
individual never received a primary series of
TT or has not received a booster dose in the
previous decade [55].
A national population-based serologic survey conducted from 1988 to 1991 showed serologic evidence of immunity declining from 80%
among persons aged 6 to 39 years to 28%
among persons 70 years or older [3]. In national
health interview surveys, only 27–36% of individuals age 65 years or older reported receiving a tetanus vaccination during the previous
ten years. More than 90% of the small number
of remaining tetanus cases in the U.S. occur in
individuals who do not know their immunization status or report having received less than
a full primary immunization series [56].
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Thus, despite serologic evidence that large
numbers of adults are susceptible, tetanus is
rare among individuals who have had their full
primary series at any previous time. This fact
suggests strongly that the protective antitoxin
standard of 0.1 IU/mL is not nearly as reliable
as a history of full immunization in predicting
protection from disease. Additional evidence of
the long-term protective effect of the primary
immunization series is the lifelong amelioration of disease severity. In more than 20 years
of CDC data, no deaths have been reported
from tetanus among individuals who have
been fully immunized at any time [56–58].
Universal diphtheria-tetanus (acellular)-pertussis (DTP/DTaP) immunization of children
has all but eliminated pediatric tetanus except
among immigrant children and other pockets
of subpar vaccine delivery, and tetanus has become primarily a disease of adults who have
never been immunized fully. Special risk factors include injection drug use and chronic
wounds, in addition to acute traumatic injuries.
The recommendations for the use of TT and
tetanus immune globulin in the treatment of
tetanus-prone wounds remain intact and
would not be affected by a decrease in the availability or utilization of tetanus boosters [56].
Tetanus-diphtheria toxoid (Td) and TT are
used almost exclusively in adults, and approximately 16 million doses are distributed annually in the U.S. [54]. Approximately one-half of
the total is delivered as part of routine care (decennial booster) and the other half in the management of tetanus-prone wounds.
Clostridium tetani is a spore-forming, grampositive bacillus. Although the organism is an
obligate anaerobe, its spores remain viable at
ambient oxygen concentrations. The spores are
resistant to extremes in temperature and humidity and can survive indefinitely. Spores are
ubiquitous in soil and in the feces of many
animals and human beings [59]. Carried into
wounds along with soil, spores may not germinate immediately because of unfavorable local
tissue conditions only to be activated after the
wound has healed, which may account for the
cases of tetanus that have no identifiable source.
When conditions favor anaerobic proliferation, the spores germinate into mature bacilli,
which then elaborate the toxins tetanolysin and
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tetanospasmin. Tetanolysin has an unclear role
in clinical tetanus; it may contribute to an
anaerobic environment by damaging viable tissue [60]. Tetanospasmin is primarily responsible for the clinical manifestations of tetanus,
entering peripheral nerves and traveling via
axonal retrograde transport to the central nervous system. Tetanospasmin then enters presynaptic neurons and disables neurotransmitter release, most importantly of the inhibitory
neurotransmitters gamma-aminobutyric acid
(GABA) and glycine. This results in disinhibition of end-organ neurons such as motor
neurons and those of the autonomic nervous
system, accounting for the muscle spasms characteristic of tetanus and the autonomic instability of severe tetanus. The rapidity of disease
onset correlates with its severity. Recovery involves synthesis of new presynaptic components and their transport to the distal axon, accounting for the typical 2–3 week period before
clinical improvement begins [60].
Clinical presentation and diagnosis. There are
four clinical forms of tetanus, depending on the
extent and location of the involved neurons:
Generalized, local, cephalic, and neonatal. In
the U.S. and other developed countries, generalized tetanus is the most common form, occurring in 80% of cases [56]. In 50–75% of cases,
the initial symptom is trismus or “lockjaw” secondary to masseter muscle spasm. Risus sardonicus, the “ironical smile” of tetanus, occurs
because of facial muscle contraction. Nuchal
rigidity and dysphagia also may be initial complaints. As the disease spreads, generalized
muscle spasms occur, either spontaneously or
in response to minor stimuli such as touch or
noise. Opisthotonus, a tonic contraction similar to decorticate posturing, is described classically. Severe spasms can result in vertebral and
long bone fractures and detachment of tendons
from their insertions. Unfortunately for the patient, mental status is not affected, and the
spasms are accompanied by severe pain [61].
In the acute phase, death results from acute
respiratory failure caused by diaphragmatic
paralysis or laryngeal spasm [60]. With intensive medical intervention, including the use of
neuromuscular blockade and mechanical ventilation, early death can be averted. In patients
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surviving beyond the acute phase, autonomic
instability becomes the major cause of death,
with a fatality rate of 11–28% [62]. Autonomic
instability appears several days after the onset
of generalized spasms and manifests most importantly as labile hypertension, tachycardia,
and pyrexia. Dysrhythmias and myocardial infarction are the most common fatal events. The
exact mechanism of the late-phase syndrome is
unclear but likely involves disinhibition of the
sympathetic nervous system. Case reports have
documented elevated concentrations of catecholamines in patients with autonomic instability; concentrations decrease with successful
treatment [63,64].
Local tetanus presents as persistent muscle
rigidity close to the site of injury. The rigidity
may linger from weeks to months but often resolves without sequelae. A caveat is that what
appears to be localized tetanus may instead be
the first sign of generalized tetanus. Local
tetanus is responsible for 13% of all tetanus
cases, and its case-fatality rate is about 1% [65].
Cephalic tetanus is an uncommon variant of
localized tetanus that involves the cranial
nerves and accounts for 6% of all cases of
tetanus [56]. Cephalic tetanus uniquely results
in nerve palsies as well as muscle spasms. The
seventh cranial nerve (CNVII) is most often involved, followed by CNVI, CNIII, CNIV, and
CNXII in decreasing order of frequency.
Cephalic tetanus also presents as trismus, but
in 42% of cases, cranial nerve deficits precede
trismus. In such cases, cephalic tetanus is easily misdiagnosed. With its predilection for
CNVII, it commonly mimics Bell’s palsy. Head
trauma and otitis media are commonly cited
etiologies. About two-thirds of patients
progress to generalized tetanus, and the overall mortality rate is 15–30% [66].
Neonatal tetanus is generalized tetanus that
occurs around the end of the first week of life.
Symptoms begin with nonspecific irritability
and poor feeding and progress rapidly to generalized spasms. The portal of entry is the
freshly cut umbilical cord. The risk of contracting neonatal tetanus is directly related to
the cleanliness of delivery conditions and to
maternal immunization because passive transfer of maternal immunoglobins is protective
[67]. Mortality is high, 50–100%, because of the
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high load of toxin in relation to body weight.
Neonatal tetanus occurs largely in developing
countries, with an estimated 80% of cases concentrated in twelve countries in Africa and
Asia [68].
The diagnosis of tetanus must be made on
clinical grounds alone, as there are no laboratory tests that can diagnose or rule it out. A protective serum antitoxin antibody concentration,
commonly accepted as 0.1 IU/mL, makes the
diagnosis of tetanus unlikely, although not impossible, as there are reports of tetanus in immunocompetent individuals having protective
antibody concentrations. Unfortunately, antitoxin antibody values are not likely to be available at the time management decisions must be
made. Fortunately, the presentation of tetanus
is so characteristic that a presumptive diagnosis is possible in most cases [69].
The differential diagnoses are few. Trismus
can be caused by peritonsillar or odontogenic
abscesses, which can be excluded by history
and physical examination. Dystonic reactions
can present as trismus. A positive response to
diphenhydramine will quickly differentiate
non-specific trismus from tetanus. Strychnine
poisoning can resemble generalized tetanus
grossly. Strychnine disables glycine release, as
does tetanospasmin, but does not affect GABA
release. There were 40 cases of strychnine poisoning in the U.S. in 1997, an incidence similar
to that of tetanus [70]. In most cases, timely
measurement of the blood strychnine concentration will not be available to the emergency
physician. Nevertheless, the test should be ordered for inpatient followup. Hypocalcemia
causing tetany is another mimic, which can easily be excluded with laboratory testing. Other
entities that cause diffuse muscle spasm, such
as seizures and encephalopathies, are accompanied by changes in mental status. Processes
that affect muscles locally, such as myopathies
or neuropathies, tend to cause weakness rather
than spasm and rigidity.
Description of tetanus toxoid, tetanus-diphtheria
toxoid, and human tetanus immune globulin.
Tetanus is preventable with proper use of TT
and human tetanus immune globulin (HTIG).
Tetanus toxoid is an inactivated form of tetanospasmin available in three forms, variably com-
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bined with diphtheria and pertussis vaccine:
DTaP, Td, and TT. DECAVAC® (Tetanus and
Diphtheria Toxoids Absorbed for Intramuscular Injection; Aventis Pasteur) is a sterile
suspension of aluminum-precipitated toxoids
in isotonic sodium chloride solution. Tetanus
and diphtheria toxins produced during the
growth of cultures are detoxified with formaldehyde and then purified separately by serial
ammonium sulfate fractionation and diafiltration [67].
The DECAVAC vaccine is supplied in a unit
dose of 0.5 mL in a preservative-free syringe.
Seroprevalance studies indicate that one-half or
more of adults in the U.S. lack what is considered a protective antitoxin concentration (0.1
IU/mL) against diphtheria [71,72]. Despite the
serologic evidence of susceptibility and the
corollary that most adults have not complied
with the decennial booster recommendation,
diphtheria remains a disease of negligible incidence in the U.S. [67]. Because diphtheria has
been a pediatric disease historically, the focus
of diphtheria immunization programs has been
children. Before the Td combination was developed in the mid-1960s, there was no recommendation for diphtheria boosters for adults.
The adult diphtheria toxoid recommendation
came about because of the availability of the
combined Td product rather than an independent concern about diphtheria [73]. Tetanusdiphtheria toxoid is the recommended preparation for active tetanus immunization and
wound management of patients older than
seven years. In such persons, Td is preferred to
single-antigen TT to enhance diphtheria protection [67].
Tetanus immune globulin (BayTet®; Bayer
Biological Products, Research Triangle Park,
NC) is a sterile solution of tetanus hyperimmune globulin for intramuscular administration. Tetanus immune globulin is prepared
by cold ethanol fractionation from the plasma
of donors immunized with TT. The inactivation
and removal of enveloped and non-enveloped
viruses during the manufacturing process has
been validated in laboratory studies [67].
Tetanus immune globulin supplies passive immunity to those individuals who have low
or no immunity. The antibodies neutralize the
free form of the powerful exotoxin produced

SURGICAL INFECTION SOCIETY GUIDELINES FOR VACCINATION

by this bacterium. Historically, such passive
protection was provided by antitoxin derived
from equine or bovine serum. However, the
foreign protein in these products often produced severe allergic manifestations, even in
individuals who demonstrated negative skin or
conjunctival tests prior to administration. Estimates of the frequency of these foreign protein
reactions after injection of equine antitoxin
range from 5–30%. If passive immunization
is needed, intramuscular injection of HTIG is
therefore the treatment of choice, as it provides
longer protection than antitoxin of animal origin and causes fewer adverse reactions [74].
Consisting of immunoglobulin (Ig)G, its halflife of 25 days ensures long-lasting protection
[75]. Intradermal injection (not recommended)
causes local irritation that does not represent
an allergy to HTIG. Intravenous injection can
cause hypotension.
Adverse reactions. Common adverse reactions
to TT, including erythema, swelling, and tenderness at the injection site, are minor and of
no long-term consequence. In a clinical study
involving individuals six years of age and
older, 19% of vaccinees noted local reactions,
whereas 2% had systemic reactions consisting
of headache, malaise, or temperature elevation.
Arthus-type hypersensitivity reactions, characterized by severe local reactions generally starting 2–8 h after the injection, may follow receipt
of TT. Such reactions may be associated with
high concentrations of circulating antitoxin in
persons who have had overly frequent injections of TT [76].
Patients who give a history of allergy to
tetanus vaccine are most likely referring to a local or nonspecific systemic reaction. These
events are not contraindications to receiving
TT. Other false contraindications include mild,
acute illness; fever; and a family history of an
adverse reaction to vaccination. Anaphylactic
reactions, neuropathies, and encephalopathies
are rare and constitute the only true contraindications to TT. Patients with a history of anaphylaxis should be referred for skin testing because they may no longer be reactive and if not,
can receive future vaccinations [67].
Adverse reactions to properly administered
HTIG are rare and consist largely of discomfort
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at the injection site and a slight temperature elevation. A history of a severe adverse reaction
likely represents previous use of equine antitoxin, which has a 10% incidence of serum sickness and a 1/100,000 incidence of fatal anaphylaxis [75]. Human tetanus immune globulin
is widely available in the U.S., so that equine
antitoxin is rarely used. In contrast, equine antitoxin is used extensively in developing countries because of greater availability and affordability.
Evidence-based recommendations. Spores of C.
tetani are ubiquitous, but serologic tests indicate that naturally acquired immunity to
tetanus toxin does not occur in the U.S. Thus,
universal primary vaccination with subsequent
maintenance of adequate antitoxin concentrations by means of appropriately timed boosters is necessary to protect all age groups [67].
After adequate immunization with TdT, it is
believed that protection persists for at least 10
years. Protection against disease is attributable
to the development of neutralizing antibodies
to tetanus and diphtheria toxin.
The efficacy of TdT used in DECAVAC vaccine was determined by comparison with a
serological correlate of protection (0.1 IU/mL)
established by the Panel on Review of Bacterial Vaccines and Toxoids [54,77]. A clinical
study to evaluate the serological responses and
adverse reactions was performed in individuals six years of age and older. Protective concentrations of antibody were achieved in more
than 90% of the study subjects after primary
immunization with both components. Booster
effects were achieved in 100% of the individuals with existing antibodies [78].
Talan et al. measured the prevalence of protective anti-tetanus antibody concentrations
in approximately 2,000 adults presenting for
wound care in five academic emergency departments. More than 90% of the patients had
anti-tetanus antibody concentrations above the
protective cutoff value of 0.1 IU/mL. Lower
prevalences of protection were found in elderly
patients, those with less education, immigrants
from countries outside North America or Western Europe, and those with an unknown vaccination history or known inadequate vaccination [79].
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TABLE 3.

RISK OF TETANUS ACCORDING
WOUND CHARACTERISTICS

Non-tetanus prone
6 h old
1 cm deep
Clean
Linear
Neurovascular intact
Not infected

TO

Tetanus prone
6 h old
1 cm deep
Contaminated
Stellate
Denervated, ischemic
Infected

Adapted from Edlich et al. [65].

Given the present low incidence of tetanus
in the U.S. and the relatively high prevalence
of protective tetanus antitoxin in individuals
who are not members of defined risk groups,
questions have arisen regarding the appropriateness of the ACIP guidelines for tetanus
prophylaxis in wound care [79]. Nevertheless, the current recommendations should be
maintained for several reasons. As reviewed
by Wassilak and Galazka, individual antibody responses and the duration of immunity
after tetanus immunization differ widely [54].
Tetanus occurs when the amount of toxin produced by wounds contaminated with C. tetani
overwhelms available antitoxin. Periodic reports of tetanus cases occurring in the face
of protective tetanus antitoxin concentrations
support the concept that no single antibody
titer value can define minimum protection for
all patients. Anti-tetanus antibody concentrations used to define population immunity do
not guarantee individual protection [54].
Tetanus prophylaxis for the acute wound. In the
setting of an acute injury, the CDC recommendations for tetanus prophylaxis depend
on the wound characteristics and the patient’s
immunization history (Tables 3 and 4) [67].
Many characteristics of wounds encountered in
the emergency department render them nontetanus-prone: Recent; linear with sharp edges;
well vascularized; and not obviously contaminated or infected. All other wounds are considered tetanus-prone, particularly those resulting from blunt trauma and bites and those
that are grossly contaminated or infected. The
CDC recommends HTIG 250 IU, given at a site
separate from the TT to avoid interaction between the two, only for patients with tetanus-

prone wounds who have never completed a
primary immunization series. In small children, the routine dose of HTIG may be calculated by the body weight (4 IU/kg). However,
it may be advisable to administer the entire 250
IU regardless of the child’s size, because theoretically, the same amount of toxin will be produced in a child’s as in an adult’s body by the
infecting organism (53,66,76) (Grade B).
If a patient has not completed a primary
immunization series, a tetanus booster is required, and the patient will need followup
to complete the series. If the patient has had
primary immunization, a booster is given if
the last dose was more than five years previously with a tetanus-prone wound or more
than ten years previously with a non-tetanusprone wound. Patients with a contraindication
to TT must be managed with HTIG alone
[54,67,77,78] (Grade B).
Immunization in high-risk groups. Patients
from certain high-risk groups often present to
the emergency department for care and require
special attention, as standard prophylaxis may
not provide sufficient protection from tetanus.
These groups include elderly patients, human
immunodeficiency virus (HIV)-infected individuals, and intravenous drug users (IVDUs).
Because of a declining immune system, elderly patients do not respond as well to vaccination as do children and younger adults. The
formation of tetanus antibodies after vaccination is not as rapid as in younger adults, the
peak titer is not as high, and the antibodies do
not last as long [80]. In a similar fashion, the
immunogenic response to vaccination in HIVinfected individuals is blunted, and antitoxin
antibody concentrations decline more quickly
than in HIV-negative individuals. As expected,
TABLE 4.

TETANUS PROPHYLAXIS

OF

Clean
wounds
Primary immunization
Not complete
Completed 5 years
Last booster 5 years
Last booster 10 years

Td
Yes
No
No
Yes

ACUTE WOUNDS
Tetanus-prone
wounds
Td
Yes
No
Yes
Yes

HTIG
Yes
No
No
No

Adapted from ACIP [67]. See text for abbreviations.
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the response to vaccination deteriorates as HIV
infection progresses [56].
The elderly, HIV-infected, or otherwise immunocompromised patient may not have a
protective concentration of tetanus antibodies
at the time of injury, and vaccination alone may
not lead to prompt or sufficient formation of
antibodies to protect the patient. If prophylaxis
is indicated, more liberal use of HTIG may
be warranted in these patients, regardless of
primary immunization, to ensure protection
against tetanus. More frequent dosing of TT
may help sustain antibody concentrations in
the protective range. There are no official
guidelines endorsing this approach. However,
in considering the risks and benefits to a given
patient, it should be kept in mind that HTIG
and TT are safe, whereas the morbidity and
mortality associated with acute tetanus are considerable [81] (Grade E).
Intravenous drug users are a burgeoning
group at high risk for tetanus. They accounted
for 18% of all cases of tetanus between 1995 and
1997 but only 2.1–4.5% of the cases seen between 1982 and 1994 [56]. Factors that place
IVDUs at risk include low rates of immunization, contaminated drugs, repeated injection
wounds under dirty conditions, and formation
of skin abscesses and chronic ulcers, which provide ideal conditions for tetanus development
[56]. Social and behavioral factors often lead to
delayed or sporadic medical care, which compound these risk factors. Intravenous drug
users may present for complaints unrelated to
acute wounds. However, their drug use should
be considered a risk factor that requires attention to tetanus prophylaxis [56,81] (Grade E).
Post-splenectomy vaccination
The spleen was once viewed as a superfluous organ, similar to the appendix, and it was
removed with impunity if injured. It was not
until the 19th Century that the spleen was associated with immune function. The earliest association linking splenectomy to life-threatening infection was reported by Morris and
Bullock in 1919, when they demonstrated a
four-fold increase in lethal infection with Bacterium enteritidis in splenectomized rats [82].
Subsequently, King and Schumacker reported
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five cases of severe infection in infants following splenectomy for spherocytosis [83]. Subsequent reports confirmed these observations,
and the term “overwhelming post-splenectomy infection” (OPSI) was popularized by Diamond in 1969 [84].
The surgical management of splenic injuries
has evolved over the past several decades, resulting from sound scientific evaluation. Although the infectious consequences of splenectomy are well known, preventive practices
differ substantially among surgeons. Few written guidelines delineate evidence-based recommendations for vaccination, and what information is available is not well disseminated [4].
Splenic function. Because of its unique architecture and abundant blood flow, the spleen
plays a prominent role in the defense against
blood-borne organisms. Ninety percent of arterial blood flow to the spleen is directed
through the red pulp and circulates in the
meshwork of splenic cords before squeezing
through the endothelial pores of the splenic sinuses [85]. Because of the organization of the
microcirculation, blood-borne bacteria remain
in contact with splenic phagocytes, allowing
clearance of even poorly opsonized bacteria.
Invasive, encapsulated bacterial pathogens
possess a surface polysaccharide capsule that
impedes opsonization by Ig or complement in
the circulation. The spleen plays an important
role in the production of immune mediators
that aid in the clearance of bacteria and viruses.
The mediators, known as opsonins, coat circulating bacteria and viruses and convert them
into immune complexes. Although the liver
clears some of these circulating immune complexes, the spleen is predominant [85].
Several lines of evidence suggest that
splenectomized patients have compromised
humoral immunity, deficient in both complement and Ig. A particular subset of circulating
memory B cells (IgM memory B cells, which respond to bacterial polysaccharides; 86), are
absent in congenitally asplenic patients and are
severely depleted immediately after splenectomy. Memory B cells are highly specific, longlived cells generated in germinal centers after
somatic mutation, selection, and class switch,
in response to a specific etiologic agent or
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vaccine. They persist and produce antibodies
rapidly on a second challenge with the same
antigen. In humans, 30–60% of B cells are considered memory B cells, one-half of which are
IgM memory B cells. The IgM memory cells are
dependent on a functional spleen for their generation and survival and are responsible for the
T-cell-independent response to bacterial polysaccharides [87].
The spleen produces tuftsin, a tetrapeptide
(Thr-Lys-Pro-Arg) that stimulates phagocytosis. Tuftsin is part of the specific carrier molecule leukokinin, which is cleaved following
passage through the spleen, leaving a molecule
known as leukokinin-S. Tuftsin binds to specific receptors on granulocytes, monocytes,
macrophages, and natural killer cells. Once activated, tuftsin modulates the biological activities of phagocytic cells [88]. The amount of
tuftsin is significantly lower after splenectomy
[89]. Szendroi et al. demonstrated a return to
normal tuftsin concentrations in children after
splenectomy for trauma following autotransplantation of minced splenic tissue into the
omentum [90].
The spleen produces properdin, an opsonin
that plays a crucial role in the alternative pathway of complement activation. The alternative
pathway is activated in the absence of antibody, and generates both soluble and membrane-bound forms of C3 convertase, an enzyme that catalyzes the proteolysis of C3. The
alternative pathway form of C3 convertase decays rapidly unless it is stabilized by binding
with properdin. Binding of properdin with C3
convertase allows conversion of C3 to C3b.
Post-splenectomy patients lack properdin,
which may contribute to the risk of developing
OPSI [91].
An exclusive function of the spleen, pitting,
is clearance of intraerythrocyte inclusions,
while maintaining the integrity of the red blood
cell. The inclusions removed by the spleen include particulate matter, Heinz bodies (denatured hemoglobin), Howell-Jolly bodies (nuclear remnants), and Pappenheimer bodies
(iron granules) [91]. Red blood cells must deform to pass through slit-like fenestrations of
the sinus endothelium. Rigid inclusions, unable
to traverse the narrow passage, are entrapped,
excluded from the cell, and phagocytized by
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resident macrophages. Asplenic and hypersplenic patients lose their ability to clear damaged red blood cells and inclusions from the
circulation. These patients display a variety of
abnormal erythrocytes in peripheral blood
smears [91].
The spleen acts as a reservoir for platelets
and granulocytes. In non-pathologic states, the
spleen sequesters approximately 30% of the
body’s platelets, and can release them into the
circulation in response to certain stimuli. In hypersplenism secondary to portal hypertension,
the spleen can sequester as many as 90% of
platelets, resulting in severe thrombocytopenia. In contrast, there is a significant increase
in circulating platelet and granulocyte counts
after splenectomy. These counts usually normalize within a few days [91].
Overwhelming post-splenectomy infection. Overwhelming post-splenectomy infection is a fulminant, potentially life-threatening condition
that may occur weeks to years after removal of
the spleen. The precise incidence of OPSI remains controversial; published estimates differ
considerably for many reasons, including different disease definitions, duration of followup,
stratification for age, indication for splenectomy, and underlying disease [92].
The risk of post-splenectomy sepsis is highest in children, especially those under two
years of age. There are, however, reported
cases 20 to 40 years after splenectomy [93]. A
collective critical review of the literature on
OPSI from 1952 to 1987 showed that the incidence in children under 16 years of age was
4.4% with a mortality rate of 2.2%. The corresponding figures for adults were 0.9% and
0.8%. The incidence of sepsis after splenectomy
caused by trauma was 15.7% in infants and
10.4% in children younger than 5 years [94].
Splenectomy performed for a hematologic
disorder such as thalassemia, hereditary spherocytosis, or lymphoma carries a higher risk
than splenectomy performed as a result of
trauma. One recent study calculated the risk of
sepsis as 0.73 per 1,000 person-years after
splenectomy for hereditary spherocytosis [95].
Several studies reported the risk for patients
with thalassemia to range from 11–25% [94,96].
Patients with Hodgkin disease, particularly
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those who received chemotherapy, are at the
greatest risk (25–33%) [94,96].
A potential contributor to the lower rate of
infection after splenectomy for trauma is the
frequent existence of splenic implants or accessory spleens [97]. Small implants of splenic
tissue (splenosis) are found in the peritoneum
of 50% of patients who undergo splenectomy
for trauma. About 10% of such patients may
also have accessory spleens [98]. Unfortunately, the degree of protection offered by
splenosis or accessory spleens is both variable
and unpredictable. A number of cases of OPSI
have been reported in the presence of residual
splenic tissue or splenic implants [99].
Unfortunately, most of the published data on
OPSI occurrence antedate the widespread availability of the pneumococcal and Haemophilus influenzae vaccines, so the current incidence may
be lower. For example, a Danish study found
that the incidence of pneumococcal infection in
splenectomized children decreased dramatically following the introduction of the pneumococcal vaccine and the promotion of early
penicillin therapy for febrile episodes [100].
One of the most reliable reports relating to
the incidence of OPSI is that of Schwartz et al.,
who applied actuarial methods to a population
free of selection bias that had consistent longterm followup. The risk of OPSI was estimated
to be in the range of one case per 500 personyears of observation. However, the cumulative
risk of infection severe enough to necessitate
hospitalization was 33% by the end of 10 years
[101].
The time since splenectomy is also an important risk factor. Several studies have shown
that 50–70% of admissions to the hospital
for serious infections occur within the first
two years. In splenectomized young children,
80% of OPSI cases occur within this time
[98,102,103]. However, some degree of risk persists indefinitely. Thirty-three percent of postsplenectomy pneumococcal infections and 42%
of OPSI occurred more than five years postsplenectomy [104]. There also are individual
cases of OPSI reported more than 40 years after splenectomy [92].
Most serious infections after splenectomy are
caused by encapsulated bacteria. Pneumococcal infections account for approximately 50–

293

90% of reported cases, with a mortality rate
as high as 60%. Haemophilus influenzae type b,
Neisseria meningitidis, and Group A Streptococcus account for an additional 25% of infections.
Haemophilus infections are particularly important in children [92]. Other rarely implicated organisms are Capnocytophaga canimorsus (formally called DS-2), which can cause fulminant
sepsis after dog bites. Others are group B streptococci, Enterococcus spp., Bacteroides spp., and
Pseudomonas aeruginosa. Bacterial proliferation
in OPSI may be so extreme that bacteria are
noted in buffy coat preparations, extracellularly, or within neutrophils in a smear made
from unspun peripheral blood [105].
The splenectomized host is also more susceptible to infections with intraerythrocytic organisms. Protozoal infections following tick bites
(babesiosis) have been responsible for a fulminant hemolytic febrile state in asplenic individuals. Fatal falciparum malaria has been noted
more frequently in asplenic hosts [103,106].
Overwhelming post-splenectomy infection is
also known as post-splenectomy sepsis syndrome or post-splenectomy overwhelming sepsis [93,104]. Although meningitis or pneumonia
will accompany OPSI in approximately 50% of
cases, in many adults, there is no obvious source
of infection, and a cryptic source originating in
the nasopharynx is postulated. In children
younger than five years, focal infections are
more common, particularly meningitis [92].
The prodrome of OPSI may be mild and
nonspecific with flu-like symptoms of fever,
malaise, myalgia, headache, vomiting, diarrhea, or abdominal pain. Gastrointestinal
symptoms should never distract the physician
from entertaining the diagnosis of OPSI. Many
patients have had true rigors for a day or two
before receiving definitive medical management [107]. Prodromal symptoms may be followed by rapid evolution to bacteremia and
septic shock accompanied by hypotension,
anuria, and clinical evidence of disseminated
intravascular coagulation, making this syndrome a true medical emergency. Severe hypoglycemia may also be present. The subsequent clinical course often mirrors that of the
Waterhouse-Friderichsen syndrome with bilateral adrenal hemorrhages noted at autopsy
[92]. Extremity gangrene necessitating ampu-
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tation has been reported in survivors secondary to the combination of hypotension and
disseminated intravascular coagulation [107].
Despite appropriate antibiotics and intensive
therapeutic intervention, the overall mortality
rate in older published studies of established
cases of OPSI ranged from 50–70% [107,108].
More recent information suggests that when
informed patients seek medical attention
promptly, their mortality rate may be reduced
to approximately 10%. Of patients who die,
more than 80% do so within the first 48 hours
of hospital admission, illustrating the importance of early diagnosis and therapy. Among
survivors, other sequelae, in addition to gangrene and amputation, include deafness associated with either meningitis or mastoid osteomyelitis and aortic insufficiency secondary
to endocarditis [92,109].
Vaccines. The first pneumococcal polysaccharide vaccine was released in the 1940s, but was
withdrawn from the market when penicillin
and sulfonamide drugs became widely available, primarily on the assumption that pneumococcal disease would be eradicated by antibiotics. When this proved to be untrue, and
the morbidity and mortality of pneumococcal
disease once again were recognized, pneumococcal vaccines were re-licensed in the U.S. in
1977, when a 14-valent polysaccharide vaccine
was released, to be replaced by a 23-valent vaccine in 1980. In February 2000, a 7-valent protein conjugate pneumococcal vaccine was licensed for pediatric use in the U.S. [110].
At least 90 serotypes of Streptococcus pneumoniae are known. The most important virulence factor of the bacterium appears to be the
polysaccharide capsule that facilitates evasion
of host defenses, as opsonization and phagocytosis of the organism leading to a humoral
immune response yields clearance and eradication. Current vaccines are based on stimulating immunity to capsular polysaccharide
antigen [110].
Three pneumococcal polysaccharide vaccines are licensed and marketed in the U.S.,
namely Pneumovax 23 (Merck, West Point,
PA), Pnu-Immune 23 (Wyeth Laboratories,
Madison, NJ) and Prevnar, a 7-valent protein
conjugate vaccine (Wyeth). The first two vac-
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cines contain 25 mcg of capsular polysaccharide from each of 23 serotypes (1, 2, 3, 4, 5, 6B,
7F, 8 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C,
19F, 19A, 20, 22F, 23F, 33F), which collectively
account for 85–90% of invasive pneumococcal
disease in adults in the U.S. Serotypes 4, 6B, 9V,
14, 18C, and 23F account for 80% of invasive
infections among U.S. children. The six pneumococcal serotypes that most frequently cause
invasive drug-resistant disease in the U.S. (6B,
9V, 14, 19A, 19F, 23F) are included in the vaccines [110,111].
The limitations of the current pneumococcal
polysaccharide vaccines have driven efforts to
develop the next generation of pneumococcal
vaccines, in particular, protein conjugates.
Serotype-specific antibody concentrations decline substantially after 5 to 10 years [112]. In
addition, current pneumococcal vaccines are Tcell-independent immunogens, and therefore
do not induce T-cell-dependent responses (i.e.,
no immunologic memory is induced). Furthermore, the vaccine is not immunogenic, and
hence is not effective, in children under the age
of two years, who suffer the highest rates of
morbidity and mortality from invasive pneumococcal infections [110].
In 2000, the 7-valent conjugated pneumococcal vaccine (Prevnar) was approved by the
Food and Drug Administration. This vaccine
contains a solution of the capsular antigens of
serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F, each
individually conjugated to a non-toxic variant
of diphtheria toxin, namely CRM 197 protein.
Conjugation of a polysaccharide to a protein
changes the nature of the anti-polysaccharide
antibody response from a T-cell-independent
to a T-cell-dependent type. This induces T
helper cells to stimulate polysaccharide-specific B cells to mature into antibody-producing
plasma cells or memory cells independent of
splenic function [113].
Concerns about efficacy surround the use of
pneumococcal vaccine. These concerns first
surfaced after the results of a national Veterans
Administration cooperative trial demonstrated
lack of efficacy in preventing pneumococcal
pneumonia [114]. Although this study influenced physicians’ perceptions of the vaccine,
the results were not statistically significant owing to a type II error in the study design [110].
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Other clinical studies have likewise failed to
demonstrate efficacy in preventing pneumococcal pneumonia in high-risk, elderly persons
[115,116], but each of these trials had serious
methodologic flaws (inadequate sample sizes,
type II errors), problems with disease definition or diagnosis, or problems with unusual
subject cohorts [116]. In contrast, studies of
South African gold miners, New Guinea highlanders, and younger persons at high risk of
pneumococcal infection but otherwise immunologically intact have demonstrated efficacy [117,118]. Similarly, studies published in
the last 20 years have demonstrated vaccine effectiveness rates of 40–100% in preventing invasive pneumococcal disease in adult, including elderly, patients [119,120].
A review of published pediatric trials demonstrated that conjugate pneumococcal vaccines,
when administered in a three-dose series at 2, 4,
and 6 months of age, are safe and more immunogenic than the polysaccharide vaccines
[121]. A trial in U.S. infants using a sevenserotype conjugate vaccine induced high titers
of type-specific antibody to all serotypes included in the vaccine, which included 78% of
the serotypes responsible for invasive disease in
children less than two years of age in the U.S.,
and induced immunologic memory to a booster
dose of polysaccharide vaccine [122].
Although safe and effective, pneumococcal
polysaccharide vaccine does have side effects.
For example, as many as 50% of recipients experience mild, self-limited local effects after the
first dose. Fortunately, moderate to severe local
or systemic reactions are rare. A review of nine
randomized controlled clinical trials of pneumococcal vaccine revealed local reactions in
fewer than one-third of recipients, and no reports of severe febrile or anaphylactic reactions
[123]. Early studies reported a higher than expected frequency and severity of systemic and
local reactions in persons receiving a second
dose of vaccine in a 2–4-year period [124]. Subsequently, it was determined that re-immunization of otherwise immunocompetent persons at
least five years after the first dose was not associated with a higher risk of adverse events or
hospitalization [125]. Published data demonstrate the safety of the pneumococcal conjugate
vaccine in infants, children, and adults [126].
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Invasive H. influenzae disease is caused by
one of six serotypes, designated “A” to “f”. Before the introduction of vaccines for H. influenzae, approximately one in 200 children developed invasive disease before the age of five
years, with a mortality rate of 4%. By 2000, H.
influenzae type B invasive disease reported to
the CDC among children under the age of
five years had declined by 96%, from 41 cases
per 100,000 in 1987, to 1.6 cases per 100,000 in
2000 [127]. Ninety-five percent of the cases of
invasive H. influenzae disease among children
younger than 5 years were caused by organisms of serotype B [128].
The first H. influenzae vaccine, introduced
in 1985, contained purified polyribosyl-ribitol
phosphate (PRP), a high molecular weight
polymer prepared from type b strains. By 1989,
the vaccine was conjugated, thereby conferring
T-cell-dependent characteristics that substantially increased the immune response. Currently, the approved H. influenzae vaccines are
conjugated to TT (PRP-T), diphtheria toxoid
(PRP-D), modified diphtheria toxoid (HbOC),
or external antigens of Neisseria meningitidis
outer membrane protein (PRP-OMT). ActHIB®
(Haemophilus influenzae B Conjugate Vaccine;
Aventis Pasteur), is a polysaccharide–protein
conjugate vaccine, with each dose of 0.5 mL formulated to contain 10 mcg of purified capsular
polysaccharide conjugated to 24 mcg of inactivated TT [129,130].
The immunogenicity of ActHIB has been
demonstrated in worldwide studies. On average, ActHIB induced anti-PRP concentrations
1.0 mcg/mL in 90% of infants after the primary series and in more than 98% of infants after a booster dose [131].
The conjugate vaccine is immunogenic in
children with sickle cell anemia, a condition
that may increase susceptibility to Haemophilus
serotype B disease. Two doses of ActHIB given
at two-month intervals induced anti-PRP antibody titers of at least 1.0 mcg/mL in 89% of
these children with a mean age of 11 months.
This is comparable to the anti-PRP antibody
titers demonstrated in normal children of similar age following two doses of ActHIB [132].
More than 7,000 infants and children two
years of age or younger received at least one
dose of ActHIB during U.S. clinical trials. Of
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these, 1,064 subjects 12–24 months of age who
received ActHIB alone had no serious or lifethreatening adverse reactions. Adverse reactions commonly associated with a first ActHIB
immunization of children 12–15 months of age,
who previously had not been immunized with
any Haemophilus conjugate vaccine, included
local pain, redness, and swelling at the injection site (2–10%). Systemic reactions included
fever, irritability, and lethargy (1–12%) [128].
Neisseria meningitidis is classified into 13
serogroups on the basis of the antigenic properties of the capsular polysaccharide. Serogroups A, B, and C account for more than 90%
of disease worldwide. Serogroups A and C predominate throughout Asia and Africa, whereas
serogroups B and C are responsible for the majority of disease in Europe and the Americas.
In the U.S., 45% of meningococcal infections are
caused by serogroup C, and as many as 40% of
infections are caused by serogroup B. In addition, in several countries, including the U.S., the
proportion of disease attributable to serogroup
Y has increased over the past decade [133].
Unlike the serogroup A and C polysaccharide antigens, serogroup B antigen is poorly immunogenic in humans. Even after a natural
infection with a serogroup B meningococcus,
antibodies against capsular polysaccharide
antigen consist primarily (more than 95%) of
IgM, with low avidity and poor bactericidal activity with human complement. The poor antigenicity of the serogroup B polysaccharide
likely is explained by its structural identity to
a glycoprotein found on human tissues, the
fundamental role of which is to modulate the
migration of neural tissues. Naturally occurring anti-B polysaccharide antibodies are present in 80% to 90% of healthy adults and in cord
sera of apparently healthy full-term babies
[134]. These naturally occurring antibodies
usually have low avidity. However, anti-B
monoclonal antibodies bind to human embryonic neural tissue in vitro [135], although no
adverse effects have been associated with the
presence of either natural or vaccine anti-B capsular polysaccharide antibody. However, overcoming the apparent immune tolerance to this
self-antigen carries the theoretical risk of inducing autoimmunity and interfering with normal cell migration [136].
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The only meningococcal vaccine currently
available in the U.S. (Menomune; Aventis Pasteur) contains polysaccharide serogroups A, C,
Y, and W-135. The vaccine therefore does not
protect against serogroup B. Each 0.5-mL dose
is formulated to contain 50 mcg of purified capsular antigen from each of the serogroups.
The immunogenicity and clinical efficacy of
the meningococcal vaccines has been established in children and adults. A study performed using four lots of Menomune in 150
adults showed at least a four-fold increase in
antibodies to all serogroups in more than 90%
of the subjects [137]. A study conducted in 73
children ages 2–12 years revealed seroconversion rates, measured by a two-fold rise in antibody titers in a solid-phase radioimmunoassay,
to be 99% for group A, 99% for group C, 97%
for group Y, and 89% for group W-135 [138].
Adverse reactions to meningococcal vaccine
are mild and consist primarily of pain and redness at the injection site for one or two days.
Pain at the site of injection is the most commonly reported adverse reaction; transient
fever developed in fewer than 2% of young
children. Adverse events reported in adults include pain and tenderness at the injection site,
occurring in 2–10% of recipients, and headache,
malaise, fever, and chills, occurring in 1–12%.
On rare occasion, IgA nephropathy has followed vaccination with Menomune; however,
a causal relation has not been established
[137,138].
Evidence-based recommendations. The organisms responsible for OPSI for which vaccines
are available are S. pneumoniae, N. meningiditis,
and H. influenzae type B. There are few controlled trials evaluating the use of vaccines in
the prevention of OPSI, but two modern reports add substantial evidence in favor of postsplenectomy vaccination. Utilizing the Danish
National Patient Registry, all children up to 15
years of age who underwent splenectomy during the period 1979 to 1987, and all children of
the same age group who were admitted to a
hospital during the same period because of S.
pneumoniae meningitis or bacteremia, were
studied [100]. A similar Danish study covering
the period 1969 to 1978, when pneumococcal
vaccine was not available, was used as a con-
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trol. During the pre-vaccine period, 4% of
splenectomized children developed invasive
pneumococcal infection, in contrast to none of
the children vaccinated during the period 1979
to 1987. Since 1982, antibiotic treatment of
splenectomized children having a fever has
been recommended in Denmark. The program
of pneumococcal vaccination and defined antibiotic prophylaxis has been highly efficacious
in preventing post-splenectomy infection in
children [100]. The second report was a series
of more than 200 asplenic adult hematology patients who had been immunized with pneumococcal vaccine, in whom only four episodes
of pneumococcal sepsis were reported in 13
years. Notably, all four of these episodes involved an infecting serotype that was not covered by the vaccine, lending indirect support
to the efficacy of the pneumococcal vaccine
even in immunocompromised patients [139].
The ACIP recommends the use of the 23-valent polysaccharide pneumococcal vaccine for
persons 2 to 64 years of age who have functional or anatomic asplenia [140] (Grade D). Because the true incidence of OPSI is unknown,
the efficacy of vaccination cannot be ascertained precisely. Although some cases of OPSI
have resulted from uncommon serotypes not
included in the vaccine, a large percentage of
post-splenectomy patients with serious pneumococcal infections were never vaccinated
[141], which suggests that pneumococcal disease is likely prevented in most vaccinated patients. True vaccine failures are uncommon
[142].
The ActHIB conjugate vaccine has been in
widespread use for infant immunizations in
the U.S. and Europe, and has reduced H. influenzae type B disease transmission, as well as
the risk to non-immunized individuals [143].
The protective concentration of HIB antibody
is not known, although previous studies have
shown that as many as 96% of adults have titers
above the presumed protective concentration
(1 mcg/mL) [144]. Therefore, some countries
do not recommend H. influenzae type B vaccination of people older than 15 years [145].
Overall, because of naturally occurring antibody, vaccination of the general population is
not recommended. However, because ActHIB
vaccine is free of any serious side effects, and
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because splenectomized individuals are more
susceptible to lethal sepsis than the general
population, 8–10% of which is attributable to
H. influenzae type B, these high-risk individuals should be considered for ActHIB conjugate
vaccine [146] (Grade D).
The available meningococcal vaccine protects against serotypes A, C, Y, and W-135 of
N. meningiditis, an important cause of bacterial
meningitis and sepsis in children and young
adults in the U.S. [147]. However, vaccination
will not eliminate the risk because the vaccine
does not protect against serotype B and because
protection against serogroups C and Y is only
partial [147]. Nevertheless, those at risk for the
disease (including asplenic patients) should be
vaccinated (Grade D).
Timing. Patients undergoing elective splenectomy should be vaccinated at least two weeks
preoperatively to maximize the antibody response against T-cell-independent immunogens. Giebink et al. demonstrated that antibody
titers were 50% lower when patients were vaccinated after splenectomy than when they were
vaccinated at least two weeks preoperatively
[148] (Grade C).
The timing of immunization after emergency splenectomy for trauma is debated, with
conflicting data supporting a variety of recommendations [4]. Part of the problem has
stemmed from studies using antibody assays,
which may be misleading. Barringer et al. studied the effect of anesthesia and splenectomy on
the antibody response to pneumococcal vaccination [149]. Measuring the antibody response
by radioimmunoassay showed no significant
difference between groups immunized preoperatively, immediately postoperatively, or
three weeks later. Similarly, Caplan et al. studied 16 patients undergoing splenectomy for
trauma and, by enzyme-linked immunosorbent
assay (ELISA), measured the antibody response
to 12 antigens in the patients and control subjects [150]. The rates of response and the geometric mean increase in the titer in the groups
were not different. The authors therefore suggested that the vaccine could be administered
in the immediate postoperative period.
Conversely, extensive studies in Denmark
led to the establishment in 1991 of national

298

guidelines for vaccination and revaccination of
splenectomized children and adults [151]. The
Danish guidelines recommend that patients
undergoing urgent or otherwise unplanned
splenectomy be immunized no less than 14
days postoperatively.
Waiting two weeks before vaccinating carries the risk of forgetting to vaccinate, but solid
data suggest that the antibody response is suboptimal when patients are vaccinated less than
14 days post-splenectomy. Shatz et al. showed
that although geometric mean antibody concentrations measured by ELISA were similar
among trauma patients immunized at postsplenectomy day 1, 7, or 14, functional antibody titers, measured by opsonophagocytosis
assay, were significantly higher in the 14-day
group [152]. This assay measures only functional antibody and eliminates non-protective
antibodies that may cross-react against the capsule or antigen, which can be falsely elevated
when measured by radioimmunoassay and
ELISA [153]. Therefore, there is likely a higher
correlation between opsonophagocytic antibody titers and pneumococcal vaccine efficacy
than between IgG antibody concentrations
measured by ELISA and efficacy [154]. Delaying vaccination beyond 14 days did not appear
to improve the immune response. In another
study by Shatz et al., antibody titers were not
significantly different in splenectomized trauma
patients vaccinated at 14 vs. 28 days postoperatively [155]. Therefore, patients undergoing
emergency splenectomy should receive immunizations 14 days later (Grade D).
Revaccination. Antibody persistence after vaccination, and the presence of an anamnestic
response with reintroduction of a specific antigen, dictate the need for and timing of revaccination. The antigens in commercial vaccines
induce the production of serotype-specific antibodies. Higher titers develop within two to
three weeks in most healthy adults, with a
comparable response occurring in anatomic or
functionally asplenic patients of the same age.
Because polysaccharide antigens alone do not
illicit a T cell response, and therefore provide
no immunologic memory, future responses to
the specific antigen depend on the circulating
antibody concentrations present at the time of
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re-exposure. Therefore, the need for revaccination of splenectomized patients is dependent
on the persistence of the antibody [4].
Mufson et al. demonstrated that five years
after immunization, in healthy adult subjects,
the titers of type-specific pneumococcal antibodies to serotypes 1, 3, 4, 8, 12F, 14, and 23F
were 90% of those obtained one month after
vaccination [156]. At 10 years, antibody concentrations measured by radioimmunoassay
remained elevated only for serotypes 4 and 8,
and were not significantly different from prevaccination levels for the other capsular antigens tested. Other studies have demonstrated
similar patterns in antibody retention lasting at
least 3 to 4 years, with a subsequent decline that
was more pronounced in splenectomized children [157].
The literature demonstrates a variety of revaccination practices. However, the CDC suggests a single booster dose for those older than
two years of age who are at high risk for serious pneumococcal infection and those most
likely to have a rapid decline in antibody titers,
which includes those with either functional
or anatomic asplenia. A single revaccination
should be given at least five years after the first
dose, with further dosing not recommended
routinely (Grade D). There currently is no recommendation to revaccinate for H. influenzae
type b or meningococcus [140].
Children younger than five years. The 7-valent
pneumococcal conjugate vaccine is recommended for all children 24–59 months of age
who are at high risk for invasive pneumococcal infection. High-risk children include those
with sickle cell disease or other types of functional or anatomic asplenia [158]. For high-risk
children 24–59 months of age who have not received either the 23-valent pneumococcal polysaccharide vaccine or the PCV7, two doses of
PCV7 should be given at an interval of six to
eight weeks, followed by a single dose of the
23-valent vaccine no less than six to eight weeks
after the last dose of PCV7. An additional dose
of the 23-valent vaccine is recommended three
to five years after the last dose [158] (Grade D).
Current immunogenicity data suggest that
PCV7 induces a primary immune response that
will provide immune memory for boosting an-
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tibody responses to some serotypes when the
23-valent vaccine is given. Because this vaccine
provides substantially expanded serotype coverage, its use is recommended for high-risk
children [158]. This age group should also receive vaccination against meningococcus and
H. influenzae type b [128,138] (Grade D).
Antibiotic prophylaxis is recommended for
all children with sickle cell disease and functional or anatomic asplenia, regardless of
whether they have received pneumococcal immunizations (Grade B). Oral administration of
penicillin V potassium is recommended at a
dose of 125 mg twice a day until three years of
age and 250 mg twice a day thereafter. Children who have not been vaccinated appropriately and who have had an invasive pneumococcal infection may discontinue penicillin
prophylaxis after five years of age [158].
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